Postes actifs de Marty J. Duvall
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Angiex, Inc.
 Angiex, Inc. Miscellaneous Commercial ServicesCommercial Services Angiex, Inc. operates as a biotechnology company, which engages in the development of an antibody-drug conjugate therapy for cancer. It focuses on TM4SF1, a membrane glycoprotein of tetraspanin topology that was originally discovered as a protein expressed on many human epithelial tumor cells. The company was founded by Paul Jaminet, Harold Dvorak, and Shou-Ching Jaminet in 2015 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 22/06/2022 | - |
| Directeur Général | 22/06/2022 | - |
Historique de carrière de Marty J. Duvall
Statistiques
Internationale
| Etats-Unis | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectorielle
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Angiex, Inc.
Angiex, Inc. Miscellaneous Commercial ServicesCommercial Services Angiex, Inc. operates as a biotechnology company, which engages in the development of an antibody-drug conjugate therapy for cancer. It focuses on TM4SF1, a membrane glycoprotein of tetraspanin topology that was originally discovered as a protein expressed on many human epithelial tumor cells. The company was founded by Paul Jaminet, Harold Dvorak, and Shou-Ching Jaminet in 2015 and is headquartered in Cambridge, MA. | Commercial Services |
- Bourse
- Insiders
- Marty J. Duvall
- Expérience
